- Home
- TORO vs ORMP Comparison
TORO vs ORMP Comparison
Compare TORO & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TORO | ORMP |
|---|---|---|
| Founded | 2022 | 2002 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 170.3M |
| IPO Year | 2022 | 2010 |
Fundamental Metrics
Financial Performance| Metric | TORO | ORMP |
|---|---|---|
| Price | $6.10 | $4.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.4K | ★ 169.4K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 36.86% | 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.74 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $2.64 | $2.06 |
| 52 Week High | $8.50 | $5.19 |
Technical Indicators
Market Signals| Indicator | TORO | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 72.65 | 66.42 |
| Support Level | $4.87 | $3.91 |
| Resistance Level | $8.50 | $5.10 |
| Average True Range (ATR) | 0.38 | 0.21 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 74.02 | 78.41 |
Price Performance
Historical ComparisonAbout TORO Toro Corp.
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.